Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.

From the US FDA’s ISTAND Program to EU’s Melloddy Initiative, and from the global challenges of real-world data to the opportunities in India, Parexel’s EVP for Clinical Data and Digital Services, chief strategy officer and India head speak on a range of topics in this interview with the Pink Sheet.

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.